Similar effects to those of ATRA were also achieved by using receptor-selective synthetic retinoids, such as the RARα agonist AM580 and the RARγ agonist R667, which were found to be effective for the suppression of subretinal fibrosis associated with proliferative retinal disease [51], suppression of retinal fibrosis [52], or the inhibition of scar formation after glaucoma filtering surgery [53]. The gene discussed is RARA; the disease is glaucoma.